相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes
Francesco Zaccardi et al.
DIABETES (2016)
Aspirin and Cancer
Paola Patrignani et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Is Long-Term Low-Dose Aspirin Therapy Associated with Renal Dysfunction in Patients with Type 2 Diabetes? JPAD2 Cohort Study
Sadanori Okada et al.
PLOS ONE (2016)
Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk
Melania Dovizio et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2015)
Cyclooxygenase inhibitors: From pharmacology to clinical read-outs
Paola Patrignani et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2015)
Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine Novel Explanation of Cardiovascular Side Effects Associated With Anti-Inflammatory Drugs
Blerina Ahmetaj-Shala et al.
CIRCULATION (2015)
Nonsteroidal Anti-Inflammatory Drugs and the Heart
Carlo Patrono et al.
CIRCULATION (2014)
Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs
Xuanwen Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia
Viviana Cavalca et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia
Carlo Patrono et al.
BLOOD (2013)
A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects
Emma J. Turtle et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Cell Selective Cardiovascular Biology of Microsomal Prostaglandin E Synthase-1
Lihong Chen et al.
CIRCULATION (2013)
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials
N. Bhala et al.
LANCET (2013)
COX-2, the dominant source of prostacyclin
Emanuela Ricciotti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system
Nicholas S. Kirkby et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Vascular COX-2 Modulates Blood Pressure and Thrombosis in Mice
Ying Yu et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Prostaglandins and Inflammation
Emanuela Ricciotti et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
The contribution of cyclooxygenase-1 and-2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy
Alfredo Dragani et al.
BLOOD (2010)
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis
Matthew C. Becker et al.
AMERICAN HEART JOURNAL (2009)
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays Implications for Aspirin Resistance
Francesca Santilli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
LANCET (2009)
Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function
Dairong Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population
Luis Alberto Garcia Rodriguez et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial
John A. Baron et al.
LANCET (2008)
Mechanisms of disease:: Platelet activation and atherothrombosis
Giovanni Davi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Human pharmacology of naproxen sodium
Marta L. Capone et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis
M. Wong et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2007)
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Christopher P. Cannon et al.
LANCET (2006)
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease
Giulia Renda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
T Grosser et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Drug therapy -: Low-dose aspirin for the prevention of atherothrombosis
C Patrono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers
BF McAdam et al.
CIRCULATION (2005)
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects
ML Capone et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery
NA Nussmeier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure
TJ Aw et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus
JR Sowers et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects
ML Capone et al.
CIRCULATION (2004)
Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension
ME Widlansky et al.
HYPERTENSION (2003)
Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus -: Role of interleukin-6 and disease duration
G Davì et al.
CIRCULATION (2003)
Selective COX-2 inhibition improves endothelial function in coronary artery disease
R Chenevard et al.
CIRCULATION (2003)
Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues
MJ Thun et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Drug therapy: The coxibs, selective inhibitors of cyclooxygenase-2.
GA FitzGerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Why there are two cyclooxygenase isozymes
WL Smith et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women
LAG Rodríguez et al.
EPIDEMIOLOGY (2000)
分享论文
